Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 11/20 | 0.88 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.88 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7609424 | 1.00 | CHRM1 (0.88) | CHRM1CHRM4SIGMAR1 | |
| SCHEMBL6940009 | 0.99 | CHRM1 (0.88) | CHRM1CHRM4SIGMAR1 | |
| SCHEMBL6915595 | 0.98 | CHRM1 (0.88) | CHRM1CHRM4SIGMAR1 | |
| SCHEMBL8189299 | 0.94 | CHRM1 (1.00) | CHRM1CHRM4SIGMAR1 | |
| SCHEMBL8189336 | 0.94 | CHRM1 (1.00) | CHRM1CHRM4SIGMAR1 | |
| Oxalic Acid SCHEMBL7617644 | 0.94 | CHRM1 (0.78) | CHRM1CHRM4 | |
| Oxalic Acid SCHEMBL7617251 | 0.94 | CHRM1 (0.78) | CHRM1CHRM4 | |
| SCHEMBL8196563 | 0.93 | CHRM1 (1.00) | CHRM1CHRM4SIGMAR1 | |
| Oxalic Acid SCHEMBL7614594 | 0.92 | CHRM1 (0.77) | CHRM1CHRM4 | |
| Oxalic Acid SCHEMBL7610942 | 0.91 | CHRM1 (0.77) | CHRM1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0734259-B1 | Use of piperidine compounds in the treatment of schizophrenia | NOVO NORDISK AS (DK) | 2002-06-12 | — | — | EP | claimed |
| US-5753683-A | SCHIZOPHRENIA | NOVO NORDISK A/S (DK) | 1998-05-19 | — | — | US | claimed |
| US-5744489-A | ADMINISTERING CERTAIN 1,2,5-THIADIAZOLE AND 1,2,5-OXADIAZOLE COMPOUNDS | GREENWOOD BEVERLEY (US) | 1998-04-28 | — | — | US | claimed |
| US-20040023951-A1 | Combination therapy for treatment of psychoses | ELI LILLY AND COMPANY | 2004-02-05 | — | — | US | disclosed |
| EP-0734259-B1 | Use of piperidine compounds in the treatment of schizophrenia | NOVO NORDISK AS (DK) | 2002-06-12 | — | — | EP | disclosed |
| EP-0709094-B1 | Tetrahydropyridine oxadiazole or thiadiazole compound for treating anxiety | LILLY CO ELI (US) | 2000-04-05 | — | — | EP | disclosed |
| US-RE36375-E | Treatment of Alzheimer's disease using azacyclic compounds | NOVO NORDISK A/S (DK) | 1999-11-02 | — | — | US | disclosed |
| US-5919805-A | 3-OXY- OR THIO-DERIVATIVES OF 1,2,5-OXADIAZOLES OR 1,2,5-THIADIAZOLES; TREATMENT OF ALZHEIMER'S DISEASE, SEVERE PAINFUL CONDITIONS AND GLAUCOMA. | NOVO NORDISK A/S (DK) | 1999-07-06 | — | — | US | disclosed |
| US-5773452-A | ALZHEIMER'S DISEASE; COGNITION ACTIVATORS | NOVO NORDISK ALS (DK) | 1998-06-30 | — | — | US | disclosed |
| US-RE35822-E | COGNITION ACTIVATORS | NOVO NORDISK A/S (DK) | 1998-06-09 | — | — | US | disclosed |
| US-5753683-A | SCHIZOPHRENIA | NOVO NORDISK A/S (DK) | 1998-05-19 | — | — | US | disclosed |
| EP-0734259-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1996-10-02 | — | — | EP | disclosed |
| US-5559136-A | Treatment of Alzheimer's disease using azacyclic compounds | NOVO NORDISK A/S (DK) | 1996-09-24 | — | — | US | disclosed |
| US-5545638-A | USING A 3-(TETRAHYDROPYRID-3-YL-) SUBSTITUTED (OXA- OR THIA-)DIAZOLE COMPOUND | NOVO NORDISK A/S (DK) | 1996-08-13 | — | — | US | disclosed |
| WO-1996014066-A1 | A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS | NOVO NORDISK A/S (DK) | 1996-05-17 | — | — | WO | disclosed |
| EP-0709094-A2 | Method for treating anxiety using a tetrahydropyridine oxadiazole or thiadiazole compound | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | disclosed |
| EP-0687265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1995-12-20 | — | — | EP | disclosed |
| WO-1995005174-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1995-02-23 | — | — | WO | disclosed |
| US-5376668-A | Cholinergic agents as cognition activators in treatment of Alzheimer*s disease | NOVO NORDISK A/S (DK) | 1994-12-27 | — | — | US | disclosed |
| WO-1994020495-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023951-A1 | Combination therapy for treatment of psychoses | CHRM5, CHRM4, CHRM2 | CHRM1 8/4885CHRM4 2/4885SIGMAR1 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.